AbCellera Biologics
ABCL
62 hedge funds and large institutions have $2.74B invested in AbCellera Biologics in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
25.65% more ownership
Funds ownership: 0% → 25.65% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$882M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$478M |
| 3 |
O
OrbiMed
New York
|
+$384M |
| 4 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$309M |
| 5 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
+$188M |
Top Sellers
ABCL Hedge Fund Activity: Q4 2020 in Review
62 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2020, worth a combined $2.74B.
Buyers outnumbered sellers: 62 funds opened new ABCL positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $882M.
- 62 institutional investors held AbCellera Biologics (ABCL) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $2.74B of AbCellera Biologics stock for Q4 2020.
- 62 funds opened new AbCellera Biologics positions in Q4 2020 and 0 closed out, a net change of +62 holders.
- The largest AbCellera Biologics buyer in Q4 2020 was Viking Global Investors, an estimated $882M added.
Based on aggregated 13F filings for Q4 2020.